English
Back
Open Account
港股窩輪Jenny
commented on a stock · Mar 17 10:57

Akeso's 5-day moving average crosses above the 10-day moving average, forming a golden cross, indicating a strengthening short-term trend.

Akeso Biopharma (09926.HK) has recently shown a notable strengthening in its stock price trend, becoming a market focus. As of March 16, 2026, Akeso Biopharma closed at HKD 116.6, up 5.81% for the day, with an intraday high of HKD 117 and a trading volume of HKD 1.135 billion. The stock rebounded from a low of around HKD 93.65 in early March, accumulating a gain of over 24%, technically recovering earlier losses step by step. As of the morning session on March 17, the stock consolidated at high levels, trading at HKD 120.5, up 3.6%.
As of 10:48 AM on March 17, 2026, the performance of major Hong Kong-listed stocks in the biopharmaceutical sector is as follows: Zai Lab (09688.HK) $ZAI LAB (09688.HK)$ traded at HKD 15.16, up 3.77%; Innovent Bio (01801.HK) $INNOVENT BIO (01801.HK)$ traded at HKD 85.7, up 1.90%; Wuxi Bio (02269.HK) $WUXI BIO (02269.HK)$ traded at HKD 36.12, up 3.61%; Genscript Biotech (01548.HK) $GENSCRIPT BIO (01548.HK)$ traded at HKD 11.86, up 5.61%.
Technical Analysis: Short-term strength, but consolidation needed near resistance zone
The stock price has stabilized above the 5, 10, and 20-day short-term moving averages, with the moving averages showing a bullish alignment; upward momentum remains in the short term.
The current stock price is approaching the 60-day line, 120-day line, and the upper Bollinger Band, all near HKD 117, marking a key technical resistance zone.
The RSI indicator is above 50, showing a clear uptrend but not yet at an extreme overbought level. There is a short-term need for consolidation and fluctuation.
Key levels:
First resistance above: $120.9; if broken through, the next target is $131.5.
First support below: $105.6 (near the 10-day moving average); if it breaks down, look for $101.7 as the previous platform support.
Akeso (09926.HK) has recently shown a notable strengthening in its share price performance, becoming a market focus. As of March 16, 2026, Akeso closed at HK$116.6, up 5.81% for the day, with an intraday high of HK$117 and a trading volume reaching HK$1.135 billion. The stock rebounded from its early March low near HK$93.65, with cumulative gains exceeding 24%, and technically, it is gradually recovering previous losses. As of the morning session on March 17, the stock consolidated near its highs, trading at HK$120.5, with a gain of 3.6%. As of 10:48 AM on March 17, 2026, the performance of major Hong Kong-listed biopharmaceutical stocks is as follows: Zai Lab (09688.HK) $ZAI LAB (09688.HK)$ trading at HK$15.16, up 3.77%; Innovent Bio (01801.HK) $INNOVENT BIO (01801.HK)$ trading at HK$85.7, up 1.90%; Wuxi Bio (02269.HK) $WUXI BIO (02269.HK)$ trading at HK$36.12, up 3.61%; Genscript Biotech (01548.HK) $GENSCRIPT BIO (01548.HK)$ trading at HK$11.86, up 5.61%. Technical Analysis: Short-term bias is bullish, but consolidation is needed near resistance levels. The share price has stabilized above the 5, 10, and 20-day short-term moving averages, which are aligned in a bullish pattern; short-term upward momentum remains intact. The current stock price is close to the 60-day line, 1...
Fundamentals and Market: Continuous positive developments, with improving sentiment in the sector.
The novel tri-specific antibody drug AK150 received clinical approval from the NMPA. This marks the company’s first tri-specific antibody to enter clinical trials, representing a world-first product category, further enriching its R&D pipeline and acting as a positive catalyst for the stock price.
The company will announce its full-year 2025 results on March 26, which will serve as a key guide for the next phase of the stock price movement.
Institutions generally remain optimistic about the long-term development. First Shanghai and CITIC Construction maintain their positive outlooks. The innovative drug sector remains active, providing a favorable market environment for Akeso Biopharma.
March 16 [HKEX Podcast] Hang Seng Index, CATL, BYD, China Tourism Group Duty Free, Hua Hong Semiconductor, Akeso Biopharma
Reviewing the analysis from the [Hong Kong Stock Podcast] on March 16, the show noted that after rebounding from recent lows, Akeso Biopharma's stock price has been gradually recovering. Short-term moving averages are trending upward, and the stock price is trading above various short- to medium-term moving averages, indicating continued short-term upward momentum. The show specifically mentioned that the stock price is approaching the 120-day moving average (around $117) and the upper Bollinger Band (also around $117), making this area a key technical level for short-term market observation. The RSI is above 50, signaling strong market momentum but has not yet reached an extremely overbought level. In terms of volume, there has been an increase during the rebound from around $100 to above $110, reflecting some capital participation in the rally.
Regarding investors' concerns about whether the stock might see a pullback after rising over twenty dollars from its low to $117, the program analyzed that the stock has seen a significant rebound from its low of $93.65 to the current $116 range. Given that the price is now near the upper Bollinger Band and some long-term moving averages, this area naturally becomes an important technical point for short-term market observation. If the stock consolidates near these moving averages and the upper Bollinger Band, it would be a common technical pattern. On the other hand, if the stock can continue to hold above the short-term moving averages and gradually push higher, the market will watch for another potential test of previous highs.
Observing the trading activity in Akeso Biopharma's warrant market, recent transactions have mainly focused on call warrants, indicating that some investors are still eyeing upside opportunities after the rebound from the stock’s lows. The most active traded products have strike prices concentrated between $120 and $135, with some contracts near the $131 mark seeing notable activity. At the current price of $116, the call warrant with a strike price of $131.36 is out-of-the-money, meaning that as the stock approaches this strike price zone, the leverage effect of such products will become relatively more pronounced.
Warrant Product Review
In the review of warrant products, multiple derivative instruments related to Innovent Bio mentioned on March 12, 2026, showed significant performance in the following two trading days (up to March 16). During this period, the underlying stock Innovent Bio rose by 4.95%, while the relevant bullish products fully demonstrated leverage effects: UBS Group's bull contract performed the most prominently with a 16% increase, BOC call warrants (25994) increased by 14%, and Societe Generale's bull contract (61054) as well as Societe Generale's call warrants (25883) both rose by 13%.
Akeso (09926.HK) has recently shown a notable strengthening in its share price performance, becoming a market focus. As of March 16, 2026, Akeso closed at HK$116.6, up 5.81% for the day, with an intraday high of HK$117 and a trading volume reaching HK$1.135 billion. The stock rebounded from its early March low near HK$93.65, with cumulative gains exceeding 24%, and technically, it is gradually recovering previous losses. As of the morning session on March 17, the stock consolidated near its highs, trading at HK$120.5, with a gain of 3.6%. As of 10:48 AM on March 17, 2026, the performance of major Hong Kong-listed biopharmaceutical stocks is as follows: Zai Lab (09688.HK) $ZAI LAB (09688.HK)$ trading at HK$15.16, up 3.77%; Innovent Bio (01801.HK) $INNOVENT BIO (01801.HK)$ trading at HK$85.7, up 1.90%; Wuxi Bio (02269.HK) $WUXI BIO (02269.HK)$ trading at HK$36.12, up 3.61%; Genscript Biotech (01548.HK) $GENSCRIPT BIO (01548.HK)$ trading at HK$11.86, up 5.61%. Technical Analysis: Short-term bias is bullish, but consolidation is needed near resistance levels. The share price has stabilized above the 5, 10, and 20-day short-term moving averages, which are aligned in a bullish pattern; short-term upward momentum remains intact. The current stock price is close to the 60-day line, 1...
Warrant product recommendations and comparisons
Currently, Innovent Bio’s share price is at the HKD 116.6 level. Considering support levels of HKD 105.6 and HKD 101.7, and resistance levels of HKD 120.9 and HKD 131.5, investors can choose suitable products based on their own views.
For bullish strategies, attention can be paid to Societe Generale's call warrants (25883) and BOC call warrants (25994). Societe Generale's call warrants (25883) have an exercise price of HKD 131.36, offering about 3.3 times leverage. The key advantage of this product is that its premium and implied volatility are the lowest among similar products, making it suitable for cost-effective bullish strategies. At the current share price, the out-of-the-money range is approximately 12.6%, close to the second resistance level at HKD 131.5, making it appropriate for investors expecting the share price to break through HKD 120.9 and further test HKD 131.5. BOC call warrants (25994) have an exercise price of HKD 131.36 and provide about 3.1 times leverage. This product offers the highest leverage with relatively low premiums, making it suitable for investors seeking higher leverage.
Regarding bull contracts, one may consider Societe Generale's bull contract (61054), where the stop-loss level needs to be below the support level to provide a safety buffer. However, there is currently a lack of suitable bull contract products with appropriate stop-loss levels in the market; investors should keep an eye on newly listed products from issuers.
Two highlighted bullish products:
- Societe Generale's call warrants (25883) $SGAKESO@EC2608A.C (25883.HK)$ : Lowest premium and implied volatility, ideal cost efficiency, making it a strong choice in bullish deployment with favorable overall terms.
- BOC call warrants (25994) $BIAKESO@EC2608A.C (25994.HK)$ : Highest leverage, suitable for aggressive investors seeking higher leverage.
Akeso (09926.HK) has recently shown a notable strengthening in its share price performance, becoming a market focus. As of March 16, 2026, Akeso closed at HK$116.6, up 5.81% for the day, with an intraday high of HK$117 and a trading volume reaching HK$1.135 billion. The stock rebounded from its early March low near HK$93.65, with cumulative gains exceeding 24%, and technically, it is gradually recovering previous losses. As of the morning session on March 17, the stock consolidated near its highs, trading at HK$120.5, with a gain of 3.6%. As of 10:48 AM on March 17, 2026, the performance of major Hong Kong-listed biopharmaceutical stocks is as follows: Zai Lab (09688.HK) $ZAI LAB (09688.HK)$ trading at HK$15.16, up 3.77%; Innovent Bio (01801.HK) $INNOVENT BIO (01801.HK)$ trading at HK$85.7, up 1.90%; Wuxi Bio (02269.HK) $WUXI BIO (02269.HK)$ trading at HK$36.12, up 3.61%; Genscript Biotech (01548.HK) $GENSCRIPT BIO (01548.HK)$ trading at HK$11.86, up 5.61%. Technical Analysis: Short-term bias is bullish, but consolidation is needed near resistance levels. The share price has stabilized above the 5, 10, and 20-day short-term moving averages, which are aligned in a bullish pattern; short-term upward momentum remains intact. The current stock price is close to the 60-day line, 1...
For bearish strategies, attention can be paid to Huatai put warrants (29749) with an exercise price of HKD 95, providing 2.2 times leverage, which is the highest leverage available for bearish strategies. When selecting put warrants, note that the exercise price of HKD 95 is below the current share price, categorizing it as an out-of-the-money product. If the share price breaks below the support level at HKD 105.6, the performance of such products will be more favorable.
For bear certificates, consider Societe Generale’s bear certificate (55049) with a recovery price of $134.5, offering an actual leverage of 4.6 times. This product has the highest actual leverage and the lowest premium; another option is UBS Group's bear certificate (64129) with a recovery price of $133.45 and an actual leverage of 4.8 times, featuring high actual leverage and low premium. When choosing bear certificates, it's important to ensure that the recovery price is above the resistance levels of $120.9 and $131.5. The recovery prices of $134.5 and $133.45 are slightly higher than the second resistance level of $131.5, making them close-positioning choices suitable for investors expecting the stock price to retreat after being resisted at $120.9.
Two selected bearish products:
- HTBC Put Warrant (29749) $HUAKESO@EP2609A.P (29749.HK)$: The highest leverage, making it an ideal choice in terms of conditions for bearish deployment.
- Societe Generale Bear Certificate (55049) $SG#AKESORP2812A.P (55049.HK)$: The highest actual leverage and the lowest premium, with a recovery price of $134.5 above the resistance level, suitable for short-term bearish investors.
Overall, Akeso Inc.'s stock price is currently in a rebound recovery phase, having successfully reclaimed the $116 mark. The resistance at $120.9 will determine the short-term trend. Fundamentally, positive catalysts such as the approval of the triple antibody AK150 for clinical trials and the upcoming earnings release provide support, but technically, the stock price is approaching the upper Bollinger Band and the 120-day moving average, suggesting possible consolidation in the short term. Investors should strictly control risks when deploying, choose appropriate derivatives based on key support levels of $105.6 and $101.7 and resistance levels of $120.9 and $131.5, and be mindful of the impact of out-of-the-money levels on product performance.
Interactive Question:
Dear readers, how do you think Akeso Inc. (09926) will develop in the short term?
A) Break through the resistance at $120.9, further testing $131.5
B) Consolidate around $116, waiting for earnings guidance before moving upward
C) Technical pullback, testing support at HK$105.6 or even HK$101.7
Feel free to share your views in the comment section!
In your opinion, when choosing call warrants, which factor is more important: premium or leverage? Would you prioritize products like Societe Generale 25883 with the lowest premium, or products like BOC 25994 with higher leverage? Feel free to share your experience!
Friendly Reminder: This article does not constitute any investment advice.
This article is for reference only and does not constitute any investment advice. The market data, opinions, and analysis contained herein may change at any time without prior notice. We are not responsible for any loss or damage caused by reliance on the information in this article. Technical analysis only shows whether certain technical conditions are met; a comprehensive assessment of asset performance should combine other data and should not solely rely on this article to make trading decisions. Please note that past performance is not indicative of future results. Follow Jenny's insights on Hong Kong stock warrants for more professional analysis.
#Kangfang Biologics #09926 #HongKongStocks #TechnicalAnalysis #SupportAndResistanceLevels #Warrants #BullBearCertificates #CallOptions #PutOptions #TripleAntibodyNewDrug #HongKongWarrantsJenny
$Hang Seng Index (800000.HK)$ $Hang Seng TECH Index (800700.HK)$ $Hang Seng China Enterprises Index (800100.HK)$
Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty.Read more
Thumbs Up
1
328K Views
Report
Comments
Write a Comment...
1
11